Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer by Kong Sun-Young, Lim Hyeong-Seok, Nam Byung-Ho, Kook Myeong-Cherl, Kim Young-Woo, Ryu Keun Won, Lee Jun Ho, Choi Il Ju, Lee Jin Soo, Park Young-Iee, Kim Noe Kyeong, Park Sook Ryun in Pharmacogenomics (2009). PubMed

Abstract

S-1, an oral fluoropyrimidine, contains tegafur, which is converted to 5-fluorouracil mainly by CYP2A6. We evaluated the association between CYP2A6 polymorphisms and treatment outcome in metastatic gastric cancer patients treated with S-1 plus docetaxel.

[ hide abstract ]

Discussed In Paper

Variant Annotations

Sign in to see variant annotations.